Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. News about Disc Medicine frequently centers on its investigational pipeline, which targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Coverage of IRON often highlights regulatory and clinical milestones for bitopertin, DISC-0974, and DISC-3405. The company has reported submitting a New Drug Application for bitopertin in erythropoietic protoporphyria under the FDA’s accelerated approval pathway and receiving a Commissioner’s National Priority Voucher, a program designed to shorten review times for certain drugs. Updates also include progress in the APOLLO confirmatory trial of bitopertin.
Disc Medicine news also features data readouts and conference presentations. For DISC-0974, the company has reported initial Phase 2 results in anemia of myelofibrosis, describing substantial reductions in hepcidin, increases in iron, and positive effects on measures of anemia, as well as participation in major hematology meetings. For DISC-3405, Disc has announced Phase 2 and Phase 1b studies in polycythemia vera and sickle cell disease and has shared trial design information at scientific conferences.
Investors following IRON news will also see announcements related to public offerings of common stock and pre-funded warrants, updates on cash position and financial results, and corporate developments such as board changes, leadership appointments, and participation in investor and healthcare conferences. This combination of clinical, regulatory, financial, and corporate updates provides context for understanding Disc Medicine’s development-stage profile and strategic priorities.
Disc Medicine (NASDAQ:IRON) has appointed Nadim Ahmed to its Board of Directors. Ahmed, currently President and CEO of Cullinan Therapeutics, brings over 25 years of leadership experience in drug development and commercialization.
The appointment comes at a strategic time as Disc Medicine prepares for potential NDA filing and launch of bitopertin for EPP (erythropoietic protoporphyria). Ahmed's previous roles include President of Hematology at Bristol Myers Squibb and President of Global Hematology & Oncology at Celgene Corporation, where he oversaw multiple successful product launches.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in two major investor conferences. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5th at 10:30 a.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 1:20 p.m. ET. Both sessions will be accessible via live webcast through Disc Medicine's investor relations website, with archived replays available post-event.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management will engage in a fireside chat on Tuesday, May 20th at 9:00 am ET. Investors can access the live webcast through Disc Medicine's investor relations website at ir.discmedicine.com, with an archived replay available after the event.
Disc Medicine (NASDAQ:IRON) announces a virtual KOL investor event on May 9, 2025, focusing on anemia of myelofibrosis (MF) and its treatment landscape. The webinar will feature leading experts including:
- Dr. Aaron Gerds from Cleveland Clinic
- Dr. Prithviraj Bose from MD Anderson Cancer Center
The event will cover MF anemia's epidemiology, pathogenesis, and patient impact. Disc's leadership will present clinical data for DISC-0974, including Phase 1b trial results from the 2024 ASH meeting and ongoing Phase 2 trial design. They will discuss the expected market opportunity and timeline for interim Phase 2 data readout in 2025.
The webinar starts at 1:00 PM ET / 10:00 AM PT, with a replay available for 90 days on Disc's website.
Disc Medicine (NASDAQ:IRON) reported its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company ended 2024 with $490 million in cash and secured additional funding through a January 2025 public offering, extending operations into 2028.
Key developments include plans for bitopertin NDA submission in H2 2025 for erythropoietic protoporphyria (EPP) through accelerated approval pathway, with the APOLLO confirmatory trial set to begin mid-2025. The company presented positive data from DISC-0974's Phase 1b trial in myelofibrosis anemia and non-dialysis-dependent chronic kidney disease patients.
Financial results show R&D expenses increased to $96.7 million in 2024 from $69.3 million in 2023, while net loss widened to $109.4 million from $76.4 million. SG&A expenses rose to $33.0 million from $21.9 million, reflecting increased headcount and commercialization preparation efforts.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in hematologic disease treatments, has announced its participation in four major upcoming investor conferences in March 2025.
The company will deliver presentations at:
- TD Cowen 45th Annual Health Care Conference in Boston (March 5th, 9:10 a.m. ET)
- Leerink Global Healthcare Conference in Miami (March 10th, 2:20 p.m. ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 13th, 9:30 a.m. ET)
- Jefferies Biotech on the Beach Summit in Miami (March 11th)
Live webcasts of the presentations and fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available post-event.
Disc Medicine (NASDAQ: IRON) has announced the pricing of its upsized public offering, consisting of 3,918,182 shares of common stock at $55.00 per share and pre-funded warrants to purchase 181,818 shares at $54.9999 per warrant. The offering is expected to generate approximately $225.5 million in gross proceeds before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional $33.825 million of shares. The offering is expected to close on January 24, 2025. Proceeds will fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, and provide working capital.
Jefferies, Leerink Partners, Stifel, and Cantor are serving as joint book-running managers, with BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. as co-managers.